Present State of in vitro and in vivo Studies on Efficacy of Medical Nonspecific Protective Agents with Respect to Genotype IV Coronavirus Causing Severe Acute Respiratory Syndrome

QR Code

Present State of in vitro and in vivo Studies on Efficacy of Medical Nonspecific Protective Agents with Respect to Genotype IV Coronavirus Causing Severe Acute Respiratory Syndrome

The results of the in vitro studies on the efficacy of medical nonspecific protective agents from various pharmacological groups showed that some drugs, such as velferon, alferon, betaferon, ribavirin and lopinavir were active against TOPC virus, that permitted to recommend them for estimation of th...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. N. Shchukina, S. YA. Loginova, S. V. Borisevich, V. P. Bonderev
Format:	Article
Language:	Russian
Published:	LLC "Publishing House OKI" 2020-05-01
Series:	Антибиотики и Химиотерапия
Subjects:	evere acute respiratory syndrome virus interferon interferon inductors antiviral efficacy chemotherapy
Online Access:	https://www.antibiotics-chemotherapy.ru/jour/article/view/402
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Interferon status at the women with recurrent genital herpes in combined liposomal RNA treatment
by: A. Sh. Makhmutkhodzhayev, et al.
Published: (2012-06-01)

Virus Infections and Interferon Inductors in the Complex Therapy
by: M. G. Romantsov, et al.
Published: (2020-05-01)

Assessment of efficiency and safety of complex therapy of acute adenoviral diseases in young people
by: N. A. Malyshev, et al.
Published: (2021-06-01)

New approaches to the therapy of infectious mononucleosis
by: Yu. G. Pritulina, et al.
Published: (2021-06-01)

Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV
by: V. N. Shchukina, et al.
Published: (2020-05-01)

Toxicity Estimation of Unspecific Medicinal Antiviral Agents for Prophylaxis and Therapy of Hazard and Especially Hazard Viral Infections
by: S. YA. Loginova, et al.
Published: (2020-05-01)

Interferon Inductor Cupping of Postvaccinal Complications After Variolation
by: S. YA. Loginova, et al.
Published: (2020-05-01)

Ergoferon and Improvement of Etiopathogenetic Therapy of Influenza and Acute Respiratore Viral Infection in Adults
by: V. K. Verevshchikov, et al.
Published: (2020-05-01)

The Modern State of Prevention and Treatment of Chikungunya Fever
by: S. Ja. Loginova, et al.
Published: (2020-06-01)

INCREASED ANTI-INFLUENZA EFFICACY OF OSELTAMIVIR (TAMIFLU<sup>®</sup>) AND UMIFENOVIR (ARBIDOL<sup>®</sup>) BY COMBINED USE WITH KAGOCEL<sup>®</sup>
by: A. F. Popov, et al.
Published: (2020-05-01)

Comparative Efficacy of Etiotropic Therapy of Patients with HBeAg-Positive Chronic Hepatitis B (by the Data of the International Comparative Placebo-Controlled Study)
by: V. V. Stelmakh, et al.
Published: (2020-05-01)

ACTIVATION OF SYNTHESIS OF ENDOGENOUS INTERFERON (REVIEW)
by: V. V. Poloskov, et al.
Published: (2019-01-01)

Cycloferon and Management of Herpes Virus Infection
by: L. M. Alimbarova
Published: (2020-05-01)

Estimation of Possible Use of Interferon Inductors for Prevention of Postvaccional Reactions to TEOVac in Animal Models
by: N. K. Chernikova, et al.
Published: (2020-05-01)

Evaluation of Safety and Pharmacotherapeutic Efficacy of Cycloferon in Treatment of Astrakhan Rickettsial Fever
by: YU. V. Sherysheva, et al.
Published: (2020-05-01)

Efficacy and safety of triple therapy with recombinant interleukin-1β, recombinant interferon-α and ribavirin in patients with chronic hepatitis C, genotype 1 infection, the non-responders to previous treatment with interferon and ribavirin
by: Yu. V. Lobzin, et al.
Published: (2014-09-01)

Interferons lambda – therapeutic application
by: N. A. Kikhtenko, et al.
Published: (2020-05-01)

ADMINISTRATION CRITERIA FOR INTERFERON-BASED DRUGS AND ITS INDUCERS IN ACUTE RESPIRATORY INFECTIONS IN CHILDREN
by: E. G. Golovacheva, et al.
Published: (2014-07-01)

The Use of Interferon Inducers in an Infectious Disease Clinic
by: A. A. Shuldyakov, et al.
Published: (2020-05-01)

Planning a programme of pre-authorisation clinical trials of medicines for the treatment of chronic hepatitis C
by: A. I. Gubenko, et al.
Published: (2019-03-01)

Evaluation of the effectiveness and safety of interferon alpha-2b ointment and gel for prevention of acute respiratory infections in organized groups
by: K. V. Kozlov, et al.
Published: (2024-04-01)

The effectiveness of Interferon-Ophthalmo, an antiviral and immunotropic drug, in the treatment of adenoviral ophthalmic infections
by: E. V. Yani, et al.
Published: (2023-03-01)

PREVALENCE OF SIDE EFFECTS OF INTERFERON THERAPY IN CHILDREN WITH CHRONIC VIRAL HEPATITIS C
by: T. A. Skvortsova, et al.
Published: (2013-05-01)

Interferons : an example of communication /
by: Sanders, F. Kingsley (Frank Kingsley)
Published: (1981)

INTERFERONS AND EYE DISEASES
by: N. A. Kikhtenko, et al.
Published: (2019-06-01)

Iron metabolism in chronic hepatitis C patients on antiviral treatment
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Treatment of hepatitis C in liver transplant recipients in the Moscow Center for Liver Transplantation within 10 years
by: M. Sh. Khubutia, et al.
Published: (2016-01-01)

Potential antiviral effects of the marine probiotic Paraliobacillus zengyii on the respiratory syncytial virus
by: Qianjin Fan, et al.
Published: (2025-06-01)

INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY
by: S. P. Pyltsin, et al.
Published: (2015-01-01)

The expression of interferon-stimulated genes (interferon “signature”) in patients with rheumatoid arthritis (Preliminary results)
by: A. S. Avdeeva, et al.
Published: (2021-01-01)

Interferons alpha and gamma, pidotimod, and tilorone in the treatment of acute respiratory infections in patients with allergic rhinitis: a prospective, cohort clinical and immunological study
by: O. V. Kalyuzhin, et al.
Published: (2022-07-01)

Evaluation of the effectiveness of antiviral therapy for coronavirus infection (COVID-19) with the inclusion of recombinant interferon alpha-2b
by: A. V. Mordyk, et al.
Published: (2022-10-01)

Progress in the development and use of antiviral drugs and interferon: report of a WHO Scientific Group /
by: WHO Scientific Group
Published: (1987)

Experimental and Clinicolaboratory Evaluation of Complex Therapy Efficacy in Arboviral Infections
by: M. G. Romatsov, et al.
Published: (2020-05-01)

Aspects of a Methodological Approach to Determination of Interferon Alpha Specific Activity
by: M. L. Baykova, et al.
Published: (2020-03-01)

Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
by: T. M. Reshetnyak, et al.
Published: (2024-04-01)

Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab
by: T. M. Reshetnyak, et al.
Published: (2023-12-01)

Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)
by: A. A. Baranov, et al.
Published: (2024-06-01)

EFFICACY OF INTRAPERITONEAL INTERFERON-α ADMINISTRATION FOR TREATMENT OF ENDOMETRIOSIS IN RATS
by: R. V. Pavlov, et al.
Published: (2014-07-01)

EFFICACY AND SAFETY OF A NEW COMBINED MEDICATION WITH RECOMBINANT INTERFERON AND BETAMETHASONE IN THE TREATMENT OF HAY FEVER DURING PERIODS OF EXACERBATION
by: A. A. Ryabtseva, et al.
Published: (2016-09-01)